Hikma has once again downgraded its expectations for its generics business in 2022 as it revealed a first-half drop of 18% in sales for the unit. However, injectables and branded increases helped to offset the decline, while the company maintained that generics growth was on the horizon in 2023.
Competitive pressures in the US have led Hikma to once again slash its Generics guidance for 2022, cutting its full-year sales expectations for the unit to $650m-$675m, with a core operating margin expected to come in at 15%-16%, in the face of “persistent challenges” in the US generics market.
Challenges highlighted by Brian Hoffman, president of the Generics division, included defending some of the firm’s top products in the...
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
Steffen Wagner has taken over as Stada’s head of Germany, adding to his existing responsibilities in Europe, after Eelco Ockers stepped down from the role. Ockers’ departure comes as German generics giant Stada restructures its business to bring its branded and consumer health interests into closer alignment as part of a more streamlined model.
Video provides a powerful way to help you prove your point. When you click Online Video, you can paste in the embed code for the video you want to add. You can also type a keyword to search online for the video that best fits your document.
